NVDA
56
-3
VRSK
77
2
OKE
70
2
REGN
65
-3
MDLZ
42
4
ADT
38
-3
CMI
51
-8
FMC
33
-3
GPC
37
-3
EMR
51
3
CF
48
-5
JCI
41
3
MHK
48
2
CMS
50
2
EOG
54
2
CCL
65
-3
RHI
49
2
ACN
49
2
WMT
68
2
SWK
64
2
NVDA
56
-3
VRSK
77
2
OKE
70
2
REGN
65
-3
MDLZ
42
4
ADT
38
-3
CMI
51
-8
FMC
33
-3
GPC
37
-3
EMR
51
3
CF
48
-5
JCI
41
3
MHK
48
2
CMS
50
2
EOG
54
2
CCL
65
-3
RHI
49
2
ACN
49
2
WMT
68
2
SWK
64
2
Financhill
Back

Arcutis Biotherapeutics 10K Form

Buy
55

ARQT
Arcutis Biotherapeutics

Last Price:
9.61
Seasonality Move:
-17.15%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ARQT News And Ratings

See the #1 stock for the next 7 days that we like better than ARQT

ARQT Financial Statistics

Sales & Book Value

Annual Sales: $59.61M
Cash Flow: $-31.6M
Price / Cash Flow: 0
Annual Sales: $1.95
Price / Book: 4.94

Profitability

EPS (TTM): -2.93000
Net Income (TTM): $-217.42M
Gross Margin: $54.62M
Return on Equity: -187.25%
Return on Assets: -59.96%

Arcutis Biotherapeutics Earnings Forecast

Key Arcutis Biotherapeutics Financial Ratios

  • The Gross Profit Margin over the past 4 years for ARQT is 91.63%.
  • The Selling, General & Administrative Expenses for ARQT have been equal to 310.61% of Gross Profit Margin.
  • The Research & Development expenses have been 185.51% of Revenue.
  • The Interest Expense is -11.33% of Operating Income.
  • The Net Earning history of ARQT is -439.79% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 1 years.

Arcutis Biotherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ARQT
CUSIP: 03969K
Website: arcutis.com

Debt

Debt-to-Equity Ratio: 0.9
Current Ratio: 9.89
Quick Ratio: 9.32

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ARQT Technical Analysis vs Fundamental Analysis

Buy
55
Arcutis Biotherapeutics (ARQT) is a Buy

Is Arcutis Biotherapeutics a Buy or a Sell?